MESENCHYMAL STROMAL CELLS MAY ENHANCE RESIDUAL HEALTHY HAEMATOPOIESIS IN LOW-RISK MDS PATIENTS

被引：0
|
作者：
Jimenez Solas, T. [1 ]
Muntion Olave, S. [1 ]
Lopez, F. [1 ]
Ortega Herrera, R. [1 ]
Martin Izquierdo, M. [2 ]
Gonzalez Martinez, T. [2 ]
Janusz, K. [3 ]
Ezponda, T. [4 ]
Vilas, A. [4 ]
Alfonso, A. [5 ]
Prosper, F. [5 ]
Molero, A. [6 ]
Valcarcel, D. [7 ]
Sanchez-Guijo, F. [1 ]
Diez-Campelo, M. [1 ]
机构：
[1] Hosp Univ Salamanca, IBSAL, Hematol, Salamanca, Spain
[2] Canc Res Ctr Salamanca, Hematol, Salamanca, Spain
[3] Inst Maimonides Invest Biomed Cordoba, Biol Celular Hematol, Cordoba, Spain
[4] Univ Navarra, IDISNA, Ctr Invest Med Aplicada CIMA, Oncol Hematol, Pamplona, Spain
[5] Univ Navarra, IDISNA, Ctr Invest Med Aplicada CIMA, Hematol, Pamplona, Spain
[6] Univ Autonoma Barcelona UAB, Vall dHebron Hosp, Barcelona, Spain
[7] Vall dHebron Inst Oncol VHIO, Expt Hematol Unit, Barcelona, Spain
来源：
LEUKEMIA RESEARCH | 2021年 / 108卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P36
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [31] Tumor circulating cells in low-risk breast cancer patients
    Ferrara, F
    Pezzica, E
    Cremonesi, M
    Corti, D
    Makovec, E
    Ciotti, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 24 - 24
  • [32] Impaired Osteogenic Differentiation Of Mesenchymal Stem Cells Derived From Bone Marrow Of Patients With Low-Risk Myelodysplastic Syndromes
    Chang, Chunkang
    Fei, Chengming
    Zhao, Youshan
    Guo, Juan
    Li, Xiao
    BLOOD, 2013, 122 (21)
  • [33] Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from MDS Patients and Promotes Leukemia Transformation
    Fu, Rong, Jr.
    Liu Zhaoyun
    Huang, Lei
    Liu, Hui
    Shao, Zonghong
    Ding, Kai
    BLOOD, 2019, 134
  • [34] Should "low-risk" thyroid cancer patients with residual thyroglobulin be retreated with iodine 131?
    Hindie, E.
    Zanotti-Fregonara, P.
    Duron, F.
    Keller, I.
    Moretti, J.
    Devaux, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S329 - S330
  • [35] Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide
    Follo, M. Y.
    Mongiorgi, S.
    Clissa, C.
    Stoyanova, M.
    Paolini, S.
    Quaranta, M.
    Martinelli, G.
    Manzoli, L.
    Cocco, C.
    Finelli, C.
    LEUKEMIA RESEARCH, 2013, 37 : S28 - S28
  • [36] Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)
    Follo, Matilde Y.
    Finelli, Carlo
    Clissa, Cristina
    Mongiorgi, Sara
    Baldazzi, Carmen
    Stanzani, Marta
    Baccarani, Michele
    Cocco, Lucia
    BLOOD, 2013, 122 (21)
  • [37] HEMATOPOIETIC GROWTH-FACTOR THERAPY FOR PATIENTS WITH MYELODYSPLASIA AT LOW-RISK FOR LEUKEMIA (MDS-LR)
    WILLEMZE, R
    BRITISH JOURNAL OF HAEMATOLOGY, 1992, 82 (01) : 236 - 236
  • [38] THE COST OF BLOOD TRANSFUSION IN LOW-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS): AN ECONOMIC ANALYSIS FOR THE CASE OF GREECE
    Fragoulakis, B.
    Maniadakis, N.
    Panagiotidis, P.
    HAEMATOLOGICA, 2012, 97 : 145 - 146
  • [39] Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS
    Li, Peng
    Alnoor, F. N. U.
    Xie, Wei
    Williams, Margaret
    Feusier, Julie
    Ding, Yi
    Zhao, Xiangrong
    Zheng, Gang
    Zhao, Chen
    Zieske, Arthur W.
    Zu, Youli
    Raess, Philipp W.
    Tantravahi, Srinivas
    Osman, Afaf
    Patel, Ami B.
    Tashi, Tsewang
    Patel, Jay L.
    Matynia, Anna P.
    Menon, Madhu P.
    Miles, Rodney R.
    Jacobsen, Jeffrey R.
    George, Tracy I.
    Sborov, Douglas W.
    Szankasi, Philippe
    Rindler, Paul
    Close, Devin
    Ohgami, Robert S.
    LEUKEMIA, 2025, 39 (01) : 248 - 256
  • [40] MORPHOTYPES AND PHENOTYPES IN PRIMARY CULTURED BONE MARROW MESENCHYMAL CELLS FROM HEALTHY DONORS AND MDS PATIENTS
    Aanei, Carmen-Mariana
    Campos-Guyotat, Lydia
    Guyotat, Denis
    Lambert, Claude
    Zugun-Eloae, Florin
    Viallet, Annie
    Carasevici, Eugen
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2009, 76B (06) : 434 - 434
12345